Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
BioXcel Therapeutics Inc (BioXcel Therapeutics) is a commercial-stage biopharmaceutical company focused on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology. The company pipeline product portfolio includes IGALMI (dexmedetomidine) sublingual film which treats schizophrenia and bipolar disorder; BXCL501 for bipolar disorders, schizophrenia and alzheimer's dementia; BXCL501 for opioid use disorder, post-traumatic stress disorder and acute stress disorder; BXCL502 targets chronic agitation in dementia; BXCL503 for apathy in dementia; and BXCL504 treats aggression in dementia. BioXcel Therapeutics is headquartered in New Haven, Connecticut, the US.
Headquarters
United States of America
Address
555 Long Wharf Dr, New Haven, Connecticut, 06511-6107
Website
www.bioxceltherapeutics.com
Telephone
1 475 2386837
No of Employees
37
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BTAI (NASD)
Revenue (2024)
$2.3M
64.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
66.7%
(2024 vs 2023)
Market Cap*
$34.9M
Net Profit Margin (2024)
XYZ
79.7%
(2024 vs 2023)
* As of and is in US$
BioXcel Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | IGALMI |
| IGALMI (Dexmedetomidine) Sublingual Film: | |
| Schizophrenia | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Plans/Strategy | In November, the company announced its plans to raise up to US$150 million in public offering of common stock. |
| 2022 | Others | In December, the company announced that the first patient was dosed in the pivotal Phase 3 TRANQUILITY III trial of BXCL501 (dexmedetomidine) sublingual film. |
| 2022 | Financing Agreements | In April, the company secured an investment of US$5 million in private financing. |
Competitor Comparison
| Key Parameters | BioXcel Therapeutics Inc | Merck & Co Inc | Pfizer Inc | Novartis AG | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Switzerland | United States of America |
| City | New Haven | Rahway | New York City | Basel | Princeton |
| State/Province | Connecticut | New Jersey | New York | Basel-Stadt | New Jersey |
| No. of Employees | 37 | 73,000 | 81,000 | 75,267 | 32,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Peter Mueller, Ph.D. | Chairman | Executive Board | 2017 | 68 |
| Vimal Mehta, Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2017 | 64 |
| Richard I. Steinhart | Chief Financial Officer; Senior Vice President | Senior Management | 2018 | 67 |
| Javier Rodriguez | Senior Vice President; Chief Legal Officer; Secretary | Senior Management | 2021 | 53 |
| Frank D. Yocca, Ph.D. | Senior Vice President; Chief Scientific Officer | Senior Management | 2018 | 69 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer